Quick Info
Status
Currently Recruiting
Estimated Enrollment
60
Phase
I
Treatment Type
Exercise
Trial Type
Sponsor
Johns Hopkins University
Primary Investigator
Nicholas Maragakis MD
Contact Information
Locations
Johns Hopkins University, Baltimore, 21287
Massachusetts General Hospital, Charlestown, 02129
Carolinas Medical Center, Charlotte, 28207
Washington University, St. Louis, 63110
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
≥70%
Months Since Onset
Number of months since first symptoms of ALS.
<60
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
Unknown
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
Unknown
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Unknown
Update Notes
No significant updates.
5/27/2015
Recruitment status updated
1/24/2014
Now recruiting people participating in certain clinical trials including tirasemtiv.
11/4/2013
Location information updated.
4/10/2013
Enrollment criteria added.
3/27/2013

Other Information

Purpose
This study will help in the development of a larger national study to understand how exercise can be combined with other treatments to potentially improve strength and alter the course of the disease.
Eligibility
18 - 80 yrs with possible, laboratory-supported probable, probable, or definite ALS
Details
Patients will exercise for 6 months using a clinical prescribed weightlifting, stationary bicycling or stretching/range of motion routine.
Collaborator(s)
  • ALS Association
News Articles and Summaries
    -
ALS Forum
-
Trial Protocol as Published on Clinicaltrials.gov
NCT01521728 (First Published: 1/24/2012)